$465 Million Settlement over a False Claims Act Allegations Against Mylan Announced by Whistleblower Institute
The Whistleblower Institute announces that Mylan reached a $465 million settlement in a whistleblower lawsuit filed by a competing pharmaceutical manufacturer, for knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed to Medicaid.
View full press release